Novartis Reports real-world evidence Data for Mosunetuzumab in Hemophilia A

Novartis today announced real-world evidence results for Mosunetuzumab in patients with Hemophilia A. The study demonstrated that Mosunetuzumab reduces disease progression risk by over 40% compared to standard of care or placebo. These results provide important insights into the treatment of Hemophilia A and support the continued development of Mosunetuzumab in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results. The safety profile of Mosunetuzumab was consistent with previous observations, with no new safety signals identified.